Navigation Links
HRT Update: Therapy May Reduce Fractures, Boost Some Risks

By Kathleen Doheny
HealthDay Reporter

MONDAY, May 28 (HealthDay News) -- Updated evidence on hormone replacement therapy for menopausal women presents good news for those at risk of osteoporosis, but a mixed bag of results regarding breast cancer and other chronic diseases.

While estrogen-only and estrogen-plus-progestin formulations reduce the risk of fractures, both increase the odds for stroke and other conditions including gallbladder disease, according to a new update of available evidence compiled for the U.S. Preventive Services Task Force, an independent expert panel that is revising its guidelines.

Estrogen-plus-progestin therapy raises the risk of breast cancer and probable dementia, while estrogen alone reduces the risk of breast cancer, the researchers found.

"We looked at all the published studies on hormone therapy for the prevention of chronic disease," said Dr. Heidi Nelson, who led the update. "What is new here is, we've taken all the results from the last 10 years and tried to distill them into the latest, most current results and how they might apply to individuals."

Some protective effects found in earlier research now appear weaker, added Nelson, a professor of medical informatics, clinical epidemiology and medicine at the Oregon Health & Science University, in Portland. Similarly, some risks look even stronger.

The findings are published online May 29 in the Annals of Internal Medicine.

Years ago, hormone therapy was often prescribed to prevent chronic conditions such as osteoporosis and cardiovascular disease. But initial results of the Women's Health Initiative study, published in 2002, found harmful effects for estrogen-plus-progestin regimens. Two years later, serious alarms were raised about estrogen-only therapy.

As a result, the task force recommended against both types of treatment for prevention of chronic disease.

Now, with about 11 years of follow-up to the Women's Health Initiative, researchers have a fuller picture, which the task force will use to update its existing guidelines.

The recommendations concern only chronic disease, not the use of hormone therapy for reducing symptoms of menopause, such as hot flashes.

For the update, Nelson and her team looked at 51 published articles, involving nine research trials, that met their criteria.

They confirmed that both estrogen alone and combination therapy reduce the risk of fractures, as found before. But they concluded that both types of treatment increase the risk of stroke, blood clots, gallbladder disease and urinary incontinence.

While estrogen alone seems to reduces the risk of breast cancer, they found stronger evidence than before that combination therapy increases the risk for breast cancer. For every 10,000 women, eight more cases of breast cancer per year are expected in those on combination therapy, Nelson said.

Women who smoke, used birth control pills or took combination therapy for symptoms of menopause have higher risks of breast cancer, they found.

Estrogen-only therapy appears to reduce invasive breast cancer by about the same amount, she said, but cautioned that it's not a reason for taking it. This effect is stronger than before, Nelson said.

Other changes: Initial results indicated that those on combination therapy had a significant increased risk for heart disease. Now, that association appears weaker, she said.

Previously, the estrogen-progestin combination was thought to protect against colon cancer. That link also looks weaker, she said.

Nelson said the differences in risks and benefits are probably explained more by the risk profiles of the women who take each therapy rather than the progestin or its lack in the therapy itself. The women have different risk factors to begin with, she said. For instance, many taking only estrogen have had a hysterectomy, with their uterus and ovaries removed, she said.

Bottom line? It does not appear wise to take hormone therapy long-term to prevent chronic conditions, she said. The best strategy remains to take the therapy, if needed for symptoms, at the lowest dose for the shortest time possible.

Given the different risks associated with estrogen-only and combination therapy, it's important to discuss your individual health history with your doctor, experts said.

Dr. Jill Rabin, chief of ambulatory care, obstetrics and gynecology at Long Island Jewish Medical Center, in New Hyde Park, N.Y., agreed that short-term, low-dose therapy for relief of symptoms is the best strategy.

Another option, she tells her patients, is to "think local." Some women are helped by estrogen cream or estrogen vaginal rings, she said.

More information

To learn more about hormone therapy, visit the U.S. National Institutes of Health.

SOURCES: Heidi D. Nelson, M.D., M.P.H., professor of medical informatics, clinical epidemiology and medicine, Oregon Health & Science University, Portland; Jill Rabin, M.D., chief of ambulatory care, obstetrics and gynecology, head of urogynecology, Long Island Jewish Medical Center, New Hyde Park, N.Y.; May 29, 2012, Annals of Internal Medicine, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Update: MedQuist Wins Contract with Detroit Medical Center for Emergency Medicine Transcription at Six Healthcare Organizations
2. Study update: Cancer information on Wikipedia is accurate, but not very readable
3. Nicotine replacement therapy is over-promoted since most ex-smokers quit unassisted
4. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
5. Longview Therapy Center, PLLC, Unveils Its Definition Of Hope
6. Short-term radiation therapy successful on breast cancer
7. ASCROs Response to NY Times Articles on Radiation Therapy Incidents
8. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
9. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
10. Behavioral therapy improves sleep and lives of patients with pain
11. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
Post Your Comments:
Related Image:
HRT Update: Therapy May Reduce Fractures, Boost Some Risks
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology: